Efficacy of low-dose 5-fluorouracil/ salicylic acid in actinic keratoses in relation to treatment duration;Wirksamkeit von niedrig-dosiertem 5-fluorouracil/salizylsäure in abhängigkeit von der behandlungsdauer bei aktinischen keratosen

JDDG - Journal of the German Society of Dermatology

Volumn 13, Issue 5, 2015, Pages 430-438

  Szeimies, Rolf Markus ^a   Dirschka, Thomas ^b,c   Prechtl, Andreas ^d   Melzer, Antje ^d  

^a Knappschaftskrankenhaus Recklinghausen   (Germany)

^b Prof Dirschka CentroDerm Klinik Wuppertal   (Germany)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

^d Almirall Hermal GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FLUOROURACIL PLUS SALICYLIC ACID; SALICYLIC ACID; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DRUG COMBINATION; KERATOLYTIC AGENT;

ACTINIC KERATOSIS; AGED; APPLICATION SITE DISCOLORATION; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; APPLICATION SITE SCABBING; BURNING SENSATION; CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG TOLERABILITY; EROSION; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; REVIEW; SKIN IRRITATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; ADULT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; GERMANY; KERATOSIS, ACTINIC; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; GERMANY; HUMANS; KERATOLYTIC AGENTS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; SALICYLIC ACID; TREATMENT OUTCOME;

EID: 84930007099     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/ddg.12685     Document Type: Review

References (24)

1. Röwert-Huber J, Patel MJ, Forschner T et al. Actinic keratosis is an early in situ squamous cell carcinoma: A proposal for reclassification. Br. J. Dermatol 2007; 156 (Suppl 3): 8-12.
2. Feldman SR, Fleischer AB. Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 2011; 87: 201-7.
3. Goldberg LH, Mamelak AJ. Review of actinic keratosis. Part I: etiology, epidemiology and clinical presentation. J Drugs Dermatol 2010; 9: 1125-32.
4. Schmitt JV, Miot HA. Actinic keratosis: A clinical and epidemiological revision. An Bras Dermatol 2012; 87: 425-34.
5. Olsen EA, Abernethy ML, Kulp-Shorten C et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24: 738-43.
6. Berman B, Amini S. Pharmacotherapy of actinic keratosis: An update. Expert Opin Pharmacother 2012; 13: 1847-71.
7. Leitlinie der Deutschen Dermatologischen Gesellschaft: Behandlung der aktinischen Keratosen. AWMF-Leitlinien- Register Nr. 013/041 (Stand: Dezember 2011).
8. Heidelberger C. Biochemical mechanisms of action of fluorinated pyrimidines. Exp Cell Res 1963; 24 (Suppl 9): 462-71.
9. Levy S, Furst K, Chern W. A comparison of the skin permeation of three topical 0.5 % fluorouracil formulations with that of a 5 % formulation. Clin Ther 2001; 23: 901-7.
10. Schlaak M, Simon JC. Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid-pilot study. J Dtsch Dermatol Ges 2010; 8: 174-8.
11. Stockfleth E, Kerl H, Zwingers T et al. Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: Histological and clinical study results. Br J Dermatol 2011; 165: 1101-8.
12. Simon J, Thiers B, Augustin M. Making proper judgement when choosing a treatment for actinic keratosis. Expert Rev Dermatol 2013; 8(6): 1-9.
13. Simon J, Dominicus R, Karl L et al. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5 % 5-fluorouracil in combination with 10.0 % salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol 2014 Sep 25. [Epub ahead of print].
14. Almirall Hermal GmbH. Fachinformation: Actikerall® 5 mg/g + 100 mg/g Lösung zur Anwendung auf der Haut, 2011.
15. Fitzpatrick TB. Soleil et peau. J de Medecine Esthetique 1975: 33-4.
16. Schaefer I, Augustin M, Spehr C et al. Prevalence and risk factors of actinic keratoses in Germany - Analysis of multisource data. J Eur Acad Dermatol Venereol 2014; 28: 309-13.
17. Criscione VD, Weinstock MA, Naylor MF et al. Actinic keratoses: Natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115: 2523-30.
18. Nashan D, Dirschka T. CME-Fortbildung Aktinische Keratosen: Feldgerichtete Therapie rückt in den Fokus. Der Deutsche Dermatologe 2014; 62: 494-8.
19. Simmonds WL. Management of actinic keratoses with topical 5-fluorouracil. Cutis 1976; 18: 298-300.
20. Jeffes EW, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol 2000; 1: 167-79.
21. McIntyre WJ, Downs MR, Bedwell SA. Treatment options for actinic keratoses. Am Fam Physician 2007; 76: 667-71.
22. Stockfleth E, Ferrandiz C, Grob JJ et al. Development of a treatment algorithm for actinic keratoses: A European Consensus. Eur J Dermatol 2008; 18: 651-9.
23. Lebwohl M, Swanson N, Anderson LL et al. Ingenol mebutate gel for actinic keratosis. N Engl J Med 2012; 366: 1010-9.
24. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: A systematic review. Drug Saf 2009; 32: 19-31.